Cleavage of α-Synuclein by Calpain: Potential Role in Degradation of Fibrillized and Nitrated Species of α-Synuclein
α-Synuclein (α-syn) is a major protein component of the neuropathological hallmarks of Parkinson's disease and related neurodegenerative disorders termed synucleinopathies. Neither the mechanism of α-syn fibrillization nor the degradative process for α-syn has been elucidated. Previously, we sh...
Saved in:
Published in | Biochemistry (Easton) Vol. 44; no. 21; pp. 7818 - 7829 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Chemical Society
31.05.2005
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | α-Synuclein (α-syn) is a major protein component of the neuropathological hallmarks of Parkinson's disease and related neurodegenerative disorders termed synucleinopathies. Neither the mechanism of α-syn fibrillization nor the degradative process for α-syn has been elucidated. Previously, we showed that wild-type, mutated, and fibrillar α-syn proteins are substrates of calpain I in vitro. In this study, we demonstrate that calpain-mediated cleavage near and within the middle region of soluble α-syn with/without tyrosine nitration and oxidation generates fragments that are unable to self-fibrillize. More importantly, these fragments prevent full-length α-syn from fibrillizing. Calpain-mediated cleavage of α-syn fibrils composed of wild-type or nitrated α-syn generate C-terminally truncated fragments that retain their fibrillar structure and induce soluble full-length α-syn to co-assemble. Therefore, calpain-cleaved soluble α-syn inhibits fibrillization, whereas calpain-cleaved fibrillar α-syn promotes further co-assembly. These results provide insight into possible disease mechanisms underlying synucleinopathies since the formation of α-syn fibrils could be causally linked to the onset/progression of these disorders. |
---|---|
Bibliography: | istex:9B219DB24F948A9E8707B7B83937DA206D217936 ark:/67375/TPS-2ML1431S-D This work was supported in part by grants from the National Institute of Aging (to V.M.-Y.L. and H.I.), National Institute of Neurological Disorders and Stroke (to D.R.L.), National Parkinson's Foundation (to D.R.L.), and American Parkinson's Disease Association (to A.J.M.-E.). ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
ISSN: | 0006-2960 1520-4995 |
DOI: | 10.1021/bi047846q |